-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the State Medical Products Administration (NMPA) conditionally approved the listing of Mobosetinib succinate capsules (trade name: ENVIRIX/EXKIVITY) declared by Takeda Pharmaceutical Co.
, Ltd.
through the priority review and approval process
.
It is indicated for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) who progress during or after platinum-containing chemotherapy and carry an epidermal growth factor receptor (EGFR) exon 20 insertion mutation
.
Mobosetinib is an irreversible tyrosine kinase inhibitor
targeting EGFR exon 20 insertion mutations.
The launch of this drug provides a new treatment option
for patients with advanced non-small cell lung cancer who carry EGFR exon 20 insertion mutation positive.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).